New Evaluations Available to Study Effect of Drugs on Platelet Numbers and Function

July 10, 2012 - Because platelets are the first line of defense against vascular bleeding and are major contributors to thrombosis and inflammation, observation of decreases in platelet counts and/or alterations in platelet function are important findings in regulatory preclinical studies.

The immunology and clinical pathology groups at Charles River provide services to support your need to evaluate the potential effect of your compound on platelet numbers and/or function. Our experience includes evaluation of various types of test articles, including, but not limited to, monoclonal antibodies, small molecules, proteins and peptides.

The methods listed below are offered by Charles River and allow for the evaluation of drug-induced platelet decreases and dysfunction. 

Evaluation of Decreased Platelet Counts:

• Platelet Parameters
• Mean platelet volume (MPV)
• Platelet distribution width (PDW)
• Plateletcrit or thrombocrit (PCT)
• Mean platelet component concentration (MPC)
• Platelet component concentration distribution width (PCDW)
• Histopathological Evaluation
• Bone Marrow Cytological Evaluation
• Platelet Immunoglobulin Binding

Evaluation of Platelet Function:

• Aggregometry
• Flow Cytometry

To learn more about incorporating platelet evaluations into your research, please contact us at askcharlesriver@crl.com.

Related Information

• Evaluation of Drug-Induced Platelet Decreases and Dysfunction (Available only on The Source℠. Click here to login or click here to register.) 
• Immunology & Immunotoxicology
• Preclinical and Clinical Immunotoxicology Services (Available only on The Source℠. Click here to login or click here to register.) 
• T-Cell Dependant Antibody Response (TDAR) (Available only on The Source℠. Click here to login or click here to register.)